Portal de Periódicos da CAPES

Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer

2004; Karger Publishers; Volume: 67; Issue: 2 Linguagem: Inglês

10.1159/000080993

1423-0232

Maurizio Cantore, Carla Rabbi, G. Fiorentini, Cristina Oliani, D. Zamagni, Calogero Iacono, Andrea Mambrini, A. Del Freo, Andrea Manni,

Neuroendocrine Tumor Research Advances

<i>Objectives:</i> This study evaluated the clinical activity and toxicity of combination chemotherapy with irinotecan and oxaliplatin in patients with advanced pancreatic cancer that had progressed despite ≧1 course of a gemcitabine-containing regimen. <i>Methods:</i> Thirty patients with metastatic pancreatic cancer and Karnofsky performance status ≧70 received oxaliplatin 60 mg/m² on days 1 + 15 and irinotecan 60 mg/m² on days 1 + 8 + 15 every 4 weeks. Patients were assessed on the basis of clinical benefit response, changes in serum tumour marker CA 19-9, objective tumour response, time to progressive disease (TTP), and survival. <i>Results:</i> Six patients (20%) had clinical benefit response (median duration of 7.2 months). CA 19-9 levels were reduced ≧50% from baseline in 8 patients (26%) and remained stable in 8 patients. CT scans revealed that 3 patients (10%) had a partial response and 7 (23%) had stable disease. Two patients (7%) were down-staged and underwent surgery. Median TTP was 4.1 months, median survival was 5.9 months and the 1-year survival rate was 23.3%. The most serious adverse events were grade 3–4 leukopenia in 2 patients (6%), grade 3 neuropathy in 2 (6%) and grade 3 diarrhoea in 1 (3%). <i>Conclusion:</i> Chemotherapy with irinotecan and oxaliplatin is an active and well-tolerated combination in patients with advanced pre-treated pancreatic cancer.